All Issue

2025 Vol.29, Issue 3 Preview Page

Clinical or Case Report

Lenvatinib-Associated Osteonecrosis Around Long-standing Mandibular Implants: A Case Report
Min-Jun Kang1
,
Chaeyeon Lee2
,
Yongjun Cho2
,
Hyun Woong Lee3
,
Jong-Ki Huh4
,
Jae-Young Kim5*
1Fellowship, Department of Oral and Maxillofacial Surgery, Gangnam Severance Hospital, Yonsei University of College of Dentistry, Seoul, Korea
2Resident, Department of Oral and Maxillofacial Surgery, Gangnam Severance Hospital, Yonsei University College of Dentistry, Seoul, Korea
3Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
4Professor, Department of Oral and Maxillofacial Surgery, Gangnam Severance Hospital, Yonsei University College of Dentistry, Seoul, Korea
5Associate Professor, Department of Oral and Maxillofacial Surgery, Gangnam Severance Hospital, Yonsei University College of Dentistry, Seoul, Korea
*Corresponding Author
30 September 2025. pp. 170-175
PDF XML Citation
Abstract

Lenvatinib is associated with adverse effects such as osteonecrosis of the jaw (ONJ) in patients undergoing treatment for malignancies. This case report presents a 56-year-old male with hepatocellular carcinoma undergoing lenvatinib therapy who presented with ONJ with significant bone destruction surrounding mandibular implants. Bone loss was extensive and thus treated with sequestrectomy and curettage. Although healing was observed initially, an additional sequestrum was observed at the 3-month follow-up. This case highlights the potential link of lenvatinib associated ONJ. Further research is required to clarify the mechanisms underlying lenvatinib-induced ONJ and to improve management strategies.

Keywords
Hepatocellular carcinoma
Lenvatinib
MRONJ
Osteonecrosis of the jaw
References
1

Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: A review in hepatocellular carcinoma. Drugs 2019;79:665-74.

10.1007/s40265-019-01116-x
2

Mauceri R, Panzarella V, Morreale I, Campisi G. Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. Int J Oral Maxillofac Surg 2019;48:1530-2.

10.1016/j.ijom.2019.07.010
3

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American association of oral and maxillofacial surgeons’ position paper on medication-related osteonecrosis of the Jaws-2022 update. J Oral Maxillofac Surg 2022;80:920-43.

10.1016/j.joms.2022.02.008
4

Motzer RJ, Taylor MH, Evans TRJ, Okusaka T, Glen H, Lubiniecki GM, et al. Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. Expert Rev Anticancer Ther 2022;22:383-400.

10.1080/14737140.2022.203912335260027PMC9484451
5

Lenvatinib Market 2024. Industry Overview, Size, Share, Trends & Forecast till 2032. Things About Business Growth; 2024.

6

Guirguis RH, Tan LP, Hicks RM, Hasan A, Duong TD, Hu X, et al. In Vitro cytotoxicity of antiresorptive and antiangiogenic compounds on oral tissues contributing to MRONJ: systematic review. Biomolecules 2023;13.

10.3390/biom1306097337371553PMC10296421
7

Maluf G, Caldas RJ, Fregnani ER, da Silva Santos PS. A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants. Int J Implant Dent 2019;5:34.

10.1186/s40729-019-0188-031571065PMC6768921
8

Ueda N, Imada M, Kato Y, Okuda N, Nakaue K, Horita S, et al. Bevacizumab-associated implant presence-triggered osteonecrosis: A case report and literature review. J Oral Implantol 2022;48:325-31.

10.1563/aaid-joi-D-21-00155
9

Hompes D, Ruers T. Review: incidence and clinical significance of bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. Eur J Surg Oncol 2011;37:737-46.

10.1016/j.ejso.2011.06.004
10

Smeets R, Henningsen A, Jung O, Heiland M, Hammacher C, Stein JM. Definition, etiology, prevention and treatment of peri-implantitis--a review. Head Face Med 2014;10:34.

10.1186/1746-160X-10-3425185675PMC4164121
11

Tempesta A, Capodiferro S, Mauceri R, Lauritano D, Maiorano E, Favia G, et al. Peri-implantitis-like medication-related osteonecrosis of the jaw: Clinical considerations and histological evaluation with confocal laser scanning microscope. Oral Dis 2022;28:1603-9.

10.1111/odi.1387333844402PMC9541517
12

Kwon TG, Lee CO, Park JW, Choi SY, Rijal G, Shin HI. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res 2014;25:632-40.

10.1111/clr.12088
13

Boffano P, Agnone AM, Neirotti F, Bonfiglio R, Brucoli M, Ruslin M, et al. Epidemiology, etiopathogenesis, and management of MRONJ: A European multicenter study. J Stomatol Oral Maxillofac Surg 2024:101931.

10.1016/j.jormas.2024.101931
14

Giudice A, Barone S, Diodati F, Antonelli A, Nocini R, Cristofaro MG. Can surgical management improve resolution of medication-related osteonecrosis of the jaw at early stages? A prospective cohort study. J Oral Maxillofac Surg 2020;78:1986-99.

10.1016/j.joms.2020.05.037
Information
  • Publisher :The Korean Academy of Oral & Maxillofacial Implantology
  • Publisher(Ko) :대한구강악안면임플란트학회
  • Journal Title :Journal of implantology and applied sciences
  • Journal Title(Ko) :대한구강악안면임플란트학회지
  • Volume : 29
  • No :3
  • Pages :170-175
  • Received Date : 2025-06-01
  • Revised Date : 2025-09-24
  • Accepted Date : 2025-09-25
  • DOI :https://doi.org/10.32542/implantology.2025018
Journal Informaiton Journal of implantology and applied sciences Journal of implantology and applied sciences
Online Submission & Review System
  • NRF
  • 임플란트학회 전용 배너
  • KOFST
  • crossref crossmark
  • crossref cited-by
  • crossref funder-registry
  • crosscheck
  • orcid
  • open access
  • ccl
Journal Informaiton Journal Informaiton - close